ICE Index Serves as Benchmark for Taiwan's First Multi-Asset ETF Issued by KGI SITE
'This innovative index is a blend of the large cap, technology-focused equities in the NYSE® Top 10 N-Listed Index and the treasury bonds within the ICE U.S. Treasury 3-10 Year Bond Index, offering a balanced and diversified structure for users,' said Christy Chan, Head of Client Development in APAC at ICE. 'The launch of the KGI US Top Balanced ETF marks a significant milestone as Taiwan's first multi-asset ETF and the inaugural product arising out of an index collaboration between ICE and the Taipei Exchange.'
The index co-branding agreement between ICE and the Taipei Exchange (TPEx) was announced in November 2024. ICE leveraged its multi-asset class customized index capabilities to develop the index, which rebalances monthly to a 70% allocation to ten large cap, technology-focused equities, along with a 30% allocation to U.S. Treasury bonds with maturities between three and ten years, creating a rules-based, multi-asset benchmark.
'We're pleased to introduce the KGI US Top Balanced ETF, a core investment product designed to support long-term retirement planning,' said Albert Ding, the Chairman of KGI SITE. 'This ETF not only provides investors with a strategic tool for building financial security, but also embodies KGI SITE's enduring commitment to walking alongside our clients in realizing a prosperous future together.'
As interest in multi-asset strategies continues to grow globally, ICE is well-positioned to provide customers with prepackaged solutions across all asset classes to meet their evolving needs. By utilizing the ICE Custom Index tool, customers can prototype and backtest custom indices based on existing ICE indices to explore potential tailored solutions that address their specific requirements throughout the region.
For more information about ICE's Index solutions, visit: https://www.ice.com/fixed-income-data-services/index-solutions
About Intercontinental Exchange
Intercontinental Exchange, Inc. (NYSE: ICE) is a Fortune 500 company that designs, builds, and operates digital networks that connect people to opportunity. We provide financial technology and data services across major asset classes helping our customers access mission-critical workflow tools that increase transparency and efficiency. ICE's futures, equity, and options exchanges -- including the New York Stock Exchange -- and clearing houses help people invest, raise capital and manage risk. We offer some of the world's largest markets to trade and clear energy and environmental products. Our fixed income, data services and execution capabilities provide information, analytics and platforms that help our customers streamline processes and capitalize on opportunities. At ICE Mortgage Technology, we are transforming U.S. housing finance, from initial consumer engagement through loan production, closing, registration and the long-term servicing relationship. Together, ICE transforms, streamlines, and automates industries to connect our customers to opportunity.
Trademarks of ICE and/or its affiliates include Intercontinental Exchange, ICE, ICE block design, NYSE and New York Stock Exchange. Information regarding additional trademarks and intellectual property rights of Intercontinental Exchange, Inc. and/or its affiliates is located here. Key Information Documents for certain products covered by the EU Packaged Retail and Insurance-based Investment Products Regulation can be accessed on the relevant exchange website under the heading 'Key Information Documents (KIDS).'
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 -- Statements in this press release regarding ICE's business that are not historical facts are "forward-looking statements" that involve risks and uncertainties. For a discussion of additional risks and uncertainties, which could cause actual results to differ from those contained in the forward-looking statements, see ICE's Securities and Exchange Commission (SEC) filings, including, but not limited to, the risk factors in ICE's Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 6, 2025.
ICE Data Indices, LLC is the administrator of the NYSE TPEx 70-30 Equity Top 10 N-Listed & Treasury 3-10 Year Balanced Index, the NYSE® Top 10 N-Listed Index, and the ICE U.S. Treasury 3-10 Year Bond Index. Additional important information regarding these indices, including methodologies, limitations, and disclaimers, can be found at indices.ice.com. Neither any investment product mentioned herein (the 'Product'), nor the issuer of such Product, as applicable, are sponsored, endorsed, sold or promoted by ICE, its affiliates or their third-party suppliers ('ICE and its Suppliers'). ICE and its Suppliers make no representations or warranties regarding the advisability of investing in securities generally or in any investment product based on an index. Past performance of an index is not an indicator of or a guarantee of future results.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 hours ago
- Globe and Mail
1 Brilliant Quantum Computing Stock to Buy Before It Soars 70%, According to 1 Wall Street Analyst
Key Points IonQ is taking a unique approach to quantum computing. Quantum computing is expected to reach a turning point around 2030. 10 stocks we like better than IonQ › Wall Street analysts often give one-year price targets for stocks as a guide to where they think the stock is heading. While these projections are inherently flawed and in no way guarantee what will happen to a stock, understanding what the general analyst community thinks about a stock can be helpful in shaping your own research, especially in an area like quantum computing where there's a lot of hype. Kevin Garrigan from Rosenblatt Security recently set a new price target for quantum computing pure play IonQ (NYSE: IONQ). As of Wednesday's market close, IonQ was trading at $41.21 per share. Garrigan's price target is $70, indicating about 70% upside. That's a strong return in a short time frame, but is IonQ stock a buy now? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » IonQ's trapped ion approach shows potential IonQ is a leading quantum computing company, which is impressive considering that it doesn't have another business to fund its operations. IonQ relies on raising capital in the public markets and various contracts it has to fund its research, unlike many of the big tech competitors in this space, which have massive cash flows to fund their quantum computing research. Despite this disadvantage, IonQ has developed impressive quantum computing technology. IonQ has taken the trapped ion approach to quantum computing, which has benefits and drawbacks. On the plus side, trapped ion architecture has impressive fidelity, and IonQ holds the world record in 1-qubit gate fidelity tests. (A qbit, or quantum bit, is the basic unit of information used in quantum computing to encode data.) It can also be done at room temperature, while other solutions need to be cooled to absolute zero. On the downside, trapped ion quantum computing can have a slightly slower processing speed compared to other solutions. Time will tell whether this is a winning approach, but some of IonQ's early successes indicate that it could be viable. But will that be enough to deliver the $70 stock price that Garrigan thinks is possible? IonQ won't see real business gains for at least a few years Any stock price prediction for IonQ is speculation. While it has a handful of contracts and its quantum computing devices are available for use on all three major cloud computing services, there's really no commercial market for quantum computing right now. However, most quantum computing companies point toward 2030 being a key year, and IonQ is no exception. Its CEO projected that IonQ would be profitable and generate sales of nearly $1 billion by 2030. After that, management expects significant market expansion, with an $87 billion market emerging by 2035. To bridge the gap between profitability and its research phase, IonQ has $1.6 billion in cash, cash equivalents, and outside investments, which should allow it to reach this critical point. While it's impossible to know if IonQ's technology will propel it to be a winning quantum computing pick over the next few years, investors can feel confident that IonQ has the proper resources and backing to at least get to that point. Whether that's worth a $70-per-share target is a different question that I can't answer, but with all of the momentum behind quantum computing, I have a hard time seeing this stock slowing down anytime soon. As a result, I think it's worth an investment, as long as the position size is kept relatively small to help manage risk. Should you invest $1,000 in IonQ right now? Before you buy stock in IonQ, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and IonQ wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
4 hours ago
- Globe and Mail
2 Top Dividend Stocks to Buy on the Dip
Key Points Pfizer's pipeline in oncology, combined with its cost-cutting initiatives, could help it bounce back. Merck could move beyond Keytruda thanks to newer approvals and a novel formulation of the medicine. Both companies have increased their dividends at a decent rate over the past five years. 10 stocks we like better than Pfizer › Dividend stocks are a great investment choice for many reasons. Buying on the dip is even better, provided, of course, they have the means to bounce back. Investors looking for companies that fit this profile should strongly consider Pfizer (NYSE: PFE) and Merck (NYSE: MRK). These two market leaders have lagged broader equities over the trailing-12-month period, but for those focused on the long game, they still look attractive. Here's the rundown. 1. Pfizer Over the past few years, Pfizer has dealt with worsening financial results and stiff competition for some products. It also faces the prospect of losing patent protection for others; these include Eliquis, an anticoagulant that is one of its top-selling drugs, and Xtandi, a cancer treatment. Both will lose their patents in the U.S. within the next few years. These challenges have led to terrible stock-market performance. However, the sell-off may have gone too far. At current levels, Pfizer's shares look attractive. One reason the company should bounce back and continue to deliver strong returns over the long run is its deep pipeline, particularly in oncology, one of the largest therapeutic areas in the industry. Pfizer currently has five blockbuster cancer medicines, and plans to raise that number to eight by 2030. Pfizer has exciting candidates in other areas as well, and in recent years has earned approval for several new products. Though these aren't yet meaningfully contributing to its top-line growth, they should do so eventually as they earn label expansion. The company's vaccine for respiratory syncytial virus (RSV), Abrysvo, generated $143 million in sales in the second quarter, which isn't bad for a product approved in 2023. It also recently earned a label expansion in Europe for adults age 18 to 59 (it was previously indicated for those 60 and older). Pfizer should make progress with Abrysvo and other newer launches. The company has also been reducing expenses. These initiatives were likely partly responsible for Pfizer's earnings beat during the second quarter. Management intends to achieve $4.5 billion in net cost savings this year and pursue further reductions in the years ahead, efforts that should help improve profitability. Pfizer is a solid dividend stock. Its forward yield currently tops 7%, and the company has increased its payouts by 19.5% in the past five years. While the stock may take some time to recover, Pfizer could be an excellent long-term investment for income-seeking investors. 2. Merck Merck is facing several issues, none more important than increased competition for its best-selling drug, cancer medicine Keytruda, and an upcoming patent cliff in 2028 for the medicine. Also, the company's second-quarter results were not strong: Revenue declined by 2% year over year to $15.8 billion, while adjusted earnings per share declined by 7% to $2.13. However, there were some bright spots for the company. Most notably, Winrevair -- one of its newest launches, which earned approval last year -- reported sales of $336 million. Winrevair is a therapy for pulmonary arterial hypertension with a new mechanism of action. It should become a blockbuster relatively soon. Merck's business in animal health -- where it's one of the leaders -- also performed well, with sales from that segment rising by 11% year over year to $1.6 billion in the second quarter. Meanwhile, Merck has some exciting pipeline candidates that should help it overcome Keytruda-related challenges. One of them is a subcutaneous version of Keytruda, which has already aced phase 3 studies and will help extend the medicine's patent protection. Merck has also significantly improved its pipeline in recent years thanks to licensing agreements. Its candidates include promising cancer products and weight loss medicines. Just as Winrevair appears to be a major success, Merck is also likely to develop innovative therapies that will mitigate potential Keytruda-related revenue losses. So, despite recent setbacks, the business could bounce back given Merck's history of innovation. Turning to Merck's dividend program, the company now offers a forward yield of 4.1%, with its dividends increasing by 39% over the past five years. The stock remains a good pick for dividend seekers. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,155!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,106,071!* Now, it's worth noting Stock Advisor's total average return is 1,070% — a market-crushing outperformance compared to 184% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025
Globe and Mail
10 hours ago
- Globe and Mail
3 ETFs That Could Generate $1 Million in Passive Income
Key Points If you were earning an average dividend yield of, say, 3%, you'd need a huge portfolio to generate $1 million in passive income from dividends. A smaller portfolio can still produce meaningful amounts of dividend income. Dividend-focused ETFs make dividend investing easy. 10 stocks we like better than Schwab U.S. Dividend Equity ETF › We're all going to need income in retirement, and that could come from shaving off some of our assets every year -- for instance, selling shares of stock from our portfolio. That can work, but if you live a long time, you do run the risk of running out of dollars before you run out of breath. So, consider generating passive income from some great exchange-traded funds (ETFs) -- funds that trade like stocks. For my own retirement, I plan to generate a significant amount of income passively via dividends from dividend-paying stocks. I own various dividend payers along with a dividend-focused ETF or two. Here are three for you to consider. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Continue » Can you get $1 million in passive income? I have to say, collecting $1 million in passive income, presumably annually, is a tall order. It's not like you're going to be able to have a $2 million portfolio and a 50% dividend yield, generating $1 million. A more typical dividend yield for good blue chip companies is between 2% and 4%, with plenty of exceptions higher and lower. Some well-regarded companies do have yields of 5% or 6% or more, though. Verizon Communications (NYSE: VZ), for example, recently yielded 6.4%, and Realty Income (NYSE: O) yielded 5.7%. Meanwhile, the S&P 500 index, which holds 500 of America's biggest companies, sported an overall dividend yield of only 1.2% recently. (Many of those 500 companies don't pay a dividend at all.) So, here are some scenarios that show how much passive income you might generate with different kinds of portfolios: Portfolio Value Overall Average Dividend Yield Annual Income $500,000 3% $15,000 $1,000,000 3% $30,000 $2,000,000 3% $60,000 $33,333,333 3% $1,000,000 Source: Calculations by author. You'd need a portfolio worth $33,333,333, per the table above, if you want to collect $1 million annually via an overall average dividend yield of 3%. The table below doubles that to 6% and shows that you'd only need a $16,666,667 portfolio. Portfolio Value Overall Average Dividend Yield Annual Income $500,000 6% $30,000 $1,000,000 6% $60,000 $2,000,000 6% $120,000 $16,666,667 6% $1,000,000 Source: Calculations by author. Take some comfort in the other numbers, though. You might set up $30,000 or $60,000 or some other excellent amount of passive income with a more reasonable-sized portfolio. 3 ETFs that could generate lots of passive income for you You might now be wondering which ETFs to consider for that wonderful passive income. Here are three solid contenders: Source: Yahoo! Finance and as of August 6, 2025. Each offers a solid dividend yield along with impressive average annual gains. Such returns are not guaranteed, of course, and some ETFs will post poor or even negative results now and then. But overall, these have done well and are poised to continue. If you want fatter yields, you might consider the iShares Preferred & Income Securities ETF (NASDAQ: PFF), which recently sported a yield of 6.5%. Its average annual gains are far lower, though, as it's a fund specializing in preferred stocks, which tend to be generous dividend payers with little stock-price appreciation. Another option to consider is a covered-call ETF such as the JPMorgan Equity Premium Income ETF (NYSEMKT: JEPI) or the JPMorgan Equity Premium Income ETF (NASDAQ: JEPQ), recently yielding 8.4% and 11.2%, respectively. But read up on these kinds of ETFs first to make sure you understand what you're investing in and how they work. However you go about it, give serious consideration to loading up much of your long-term portfolio with dividend payers, as they can generate a lot of passive income for you. Should you invest $1,000 in Schwab U.S. Dividend Equity ETF right now? Before you buy stock in Schwab U.S. Dividend Equity ETF, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Schwab U.S. Dividend Equity ETF wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $663,630!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,695!* Now, it's worth noting Stock Advisor's total average return is 1,071% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Selena Maranjian has positions in JPMorgan Nasdaq Equity Premium Income ETF, Realty Income, Schwab U.S. Dividend Equity ETF, and Verizon Communications. The Motley Fool has positions in and recommends Realty Income and Vanguard Whitehall Funds-Vanguard High Dividend Yield ETF. The Motley Fool recommends Verizon Communications. The Motley Fool has a disclosure policy.
